Core Points - The report outlines a share acquisition by Zhejiang Provincial State-owned Capital Operation Co., Ltd. in Guobang Pharmaceutical Group Co., Ltd. [1][5] - The acquisition involves a total of 38,306,303 shares, representing 6.85% of the company's total share capital [6][10] - The share transfer price is set at 20.66 RMB per share, totaling approximately 791.41 million RMB [6][7] Section Summaries Section 1: Declaration - The report is prepared in accordance with relevant Chinese securities laws and regulations [1] - The information disclosing party has obtained necessary authorizations and approvals for the report [1] Section 2: Information Disclosing Party - The disclosing party is Zhejiang Provincial State-owned Capital Operation Co., Ltd., established on February 15, 2007, with a registered capital of 1 billion RMB [3][4] - The company is wholly owned by the Zhejiang Provincial Government [4] Section 3: Purpose of Equity Change and Shareholding Plan - The purpose of the equity change is driven by the disclosing party's investment needs and recognition of Guobang Pharmaceutical's development prospects [5] - There are no plans for further share increases or decreases within the next 12 months, aside from the current agreement [5] Section 4: Method of Equity Change - The equity change is executed through a share transfer agreement with three parties, resulting in the acquisition of 38,306,303 shares [6][9] - The disclosing party will become a shareholder holding more than 5% of the company post-transaction [6][10] Section 5: Recent Trading Activity - There have been no other transactions involving the buying or selling of shares in the past six months, aside from the disclosed equity change [10] Section 6: Other Significant Matters - The disclosing party confirms that all relevant information regarding the equity change has been disclosed accurately and completely [10]

Core Viewpoint - The report outlines a shareholding change in Guobang Pharmaceutical Group Co., Ltd., where the shareholder, Weifang Shiqihui Equity Investment Partnership (Limited Partnership), is transferring 4.91% of its shares to Zhejiang State-owned Capital Operation Co., Ltd. through a private agreement, resulting in a decrease in its shareholding from 8.95% to 4.04% [1][5][6]. Group 1: Shareholding Change Details - The share transfer involves 27,445,600 shares, which represents a significant reduction in the shareholder's stake [6][7]. - The agreed transfer price is 20.66 RMB per share, totaling approximately 791.41 million RMB for the entire transaction, with the transferring party receiving about 567.03 million RMB for its portion [6][7]. - The transfer is subject to compliance confirmation from the Shanghai Stock Exchange and subsequent registration with the China Securities Depository and Clearing Corporation [3][8]. Group 2: Purpose and Future Plans - The purpose of this share transfer is to introduce strategic investors who recognize the company's value and future development potential, while also meeting the needs of some shareholders to reduce their holdings [5]. - There are currently no plans for the shareholder to increase or decrease its stake in the next 12 months, aside from this transfer [5][6]. Group 3: Shareholder Information - The transferring entity, Weifang Shiqihui, is a limited partnership established on July 10, 2019, with a registered capital of 329.99 million RMB [4]. - The main responsible person of the transferring entity is Liao Shixue, who resides in Hangzhou, China [4]. Group 4: Compliance and Legal Framework - The report is prepared in accordance with the Securities Law of the People's Republic of China and relevant regulations, ensuring that all necessary authorizations and approvals have been obtained [1][2]. - The report confirms that there are no restrictions on the shares being transferred, such as pledges or freezes [8].

Core Viewpoint - Guobang Pharmaceutical's stock price increased by 0.65% to 23.07 yuan as of August 20, 2025, with a trading volume of 78,588 hands and a transaction amount of 1.79 billion yuan [1] Group 1: Company Overview - Guobang Pharmaceutical is primarily engaged in the research, development, production, and sales of pharmaceutical raw materials and animal health products [1] - The company's product range includes pharmaceutical raw materials, key pharmaceutical intermediates, and animal health products, covering two main business segments: pharmaceuticals and animal health [1] Group 2: Financial Performance - According to the 2024 annual report, the revenue distribution of Guobang Pharmaceutical is as follows: the pharmaceutical segment accounts for 64.87% of total revenue, while the animal health segment contributes 34.24% [1] Group 3: Shareholder Changes - On the evening of August 20, Guobang Pharmaceutical announced that shareholders Shiqi Hui, Hong Dehui, and Qing Shide collectively agreed to transfer 38,306,300 shares, representing 6.85% of the total share capital, to Zhejiang State-owned Capital Operation Company at a price of 20.66 yuan per share, totaling 791 million yuan [1] - Following the transfer, Zhejiang State-owned Capital Operation Company will become a strategic investor in Guobang Pharmaceutical [1] Group 4: Strategic Cooperation - The announcement indicates that the state-owned capital operation company intends to support Guobang Pharmaceutical's comprehensive development in the pharmaceutical sector, focusing on areas such as industrial chain collaboration, new business cultivation, and capital operations [1]

Group 1 - The core point of the news is that Guobang Pharmaceutical (605507) announced a share transfer agreement to introduce a strategic investor, Zhejiang State-owned Capital Operation Company, at a price of 20.66 yuan per share, totaling 791 million yuan [1][2] - After the transfer, the state-owned operation company will hold 6.85% of the shares, becoming a strategic investor without changing the controlling shareholder or actual controller of the company [1] - The transfer is aimed at optimizing the company's equity structure and introducing a strategic investor that recognizes the company's value and future development potential [1][2] Group 2 - The state-owned operation company plans to support the company's comprehensive development in the pharmaceutical field, focusing on industrial chain collaboration, new business incubation, and capital operations [1] - The collaboration will include strengthening personnel exchanges and cooperation in investment project evaluation, new technology validation, scenario applications, and think tank consulting [2] - The introduction of the state-owned operation company as a strategic investor is expected to enhance the company's core competitiveness, resource synergy, and overall operational capability [2]

本次权益变动后，仕琦汇、洪德辉及世庆德合计持有公司股份2741.1万股，占公司总股本4.91%；国有 运营公司持有公司股份3830.63万股，占公司总股本的比例为6.85%。 北京商报讯（记者 丁宁）8月20日晚间，国邦医药（605507）发布公告称，基于公司战略发展需要，引 入看好公司价值和看好公司未来发展的战略投资者，共同推动医药产业的创新发展，公司持股5%以上 股东潍坊仕琦汇股权投资合伙企业（有限合伙）（以下简称"仕琦汇"）、潍坊洪德辉股权投资合伙企业 （有限合伙）（以下简称"洪德辉"）及绍兴世庆德企业管理咨询合伙企业（有限合伙）（以下简称"世 庆德"）于8月20日与浙江省国有资本运营有限公司（以下简称"国有运营公司"）签署了《股份转让协 议》，仕琦汇、洪德辉及世庆德拟通过协议转让的方式向国有运营公司转让其首次公开发行股票前持有 的公司股份3830.63万股，占公司总股本的比例为6.85%。 ...

本次权益变动属于股份协议转让，不涉及要约收购，不会导致公司控股股东及实际控制人发生变化，不 会对公司持续稳定经营产生不利影响。 2024年1至12月份，国邦医药的营业收入构成为：医药板块占比64.87%，动物保健品板块占比34.24%， 其他占比0.48%，其他业务占比0.4%。 本次股权转让完成后，国有运营公司拟支持公司在医药领域的全面发展，在产业链协同、新业务培育、 资本运作等领域积极开展战略合作，协同公司进一步做大做强。在符合国有运营公司投资标准和要求的 前提下，国有运营公司重点支持公司主营业务相关领域的投入，双方拟在未来的合作过程中加强人员交 流，在投资项目研判、新技术论证、场景应用、智库咨询等方面开展协同赋能。具体合作内容和进度将 根据双方后续工作进一步落实和推进，尚需双方根据实际情况共同协商确定后另行签署合作协议，存在 不确定性。公司将根据规则要求及相关进展及时履行信息披露义务。敬请广大投资者注意投资风险。 国邦医药（SH 605507，收盘价：23.07元）8月20日晚间发布公告称，基于公司战略发展需要，引入看 好公司价值和看好公司未来发展的战略投资者，共同推动医药产业的创新发展，国邦医药集团股 ...

国邦医药集团股份有限公司 简式权益变动报告书 上市公司名称：国邦医药集团股份有限公司 股票上市地点：上海证券交易所 股票简称：国邦医药 股票代码：605507 信息披露义务人：潍坊仕琦汇股权投资合伙企业（有限合伙） 住所：山东省潍坊市滨海区观海路 00266 号滨海资本管理中心 5 号楼 102 室 签署日期：2025 年 8 月 20 日 国邦医药集团股份有限公司 简式权益变动报告书 信息披露义务人声明 一、信息披露义务人依据《中华人民共和国证券法》（以下简称"《证券法》"）、 《上市公司收购管理办法》（以下简称"《收购管理办法》"）、《公开发行证 券的公司信息披露内容与格式准则第 15 号—权益变动报告书》（以下简称"《准 则 15 号》"）及其他相关的法律、法规和规范性文件编写本报告书。 二、信息披露义务人签署本报告书已获得必要的授权和批准。 通讯地址：山东潍坊市滨海区香江西一街 02131 号 权益变动性质：股份减少（协议转让） 三、依据《证券法》《收购管理办法》《准则 15 号》的规定，本报告书已 全面披露信息披露义务人在国邦医药集团股份有限公司中拥有权益的股份变动 情况。 四、截至本报告书签署之日 ...

信息披露义务人：浙江省国有资本运营有限公司 注册地址：浙江省杭州市求是路8号公元大厦北楼25楼 权益变动性质：股份增加（协议受让） 上市公司名称: 国邦医药集团股份有限公司 国邦医药集团股份有限公司 简式权益变动报告书 签署日期：2025年8月20日 上市地点：上海证券交易所 股票简称：国邦医药 股票代码：605507 声 明 一、信息披露义务人依据《中华人民共和国证券法》《上市公司收购管理办 法》《公开发行证券的公司信息披露内容与格式准则第15号—权益变动报告书》 及相关法律法规编写本权益变动报告书（以下简称"本报告书"）。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违 反信息披露义务人章程和内部规则中的任何条款，或与之相冲突。 三、依据《中华人民共和国证券法》《上市公司收购管理办法》《公开发行 证券的公司信息披露内容与格式准则第15号—权益变动报告书》的规定，本报告 书已全面披露信息披露义务人在国邦医药集团股份有限公司（以下简称"国邦医 药"）中拥有权益的股份变动情况。 截至本报告书签署之日，除本报告书披露的信息外，上述信息披露义务人没 有通过任何其他方式增加或减少其在国邦医药中拥有 ...

证券代码：605507 证券简称：国邦医药 公告编号：2025-038 国邦医药集团股份有限公司 关于公司股东协议转让股份引入战略投资者暨权益 变动的提示性公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 基于公司战略发展需要，引入看好公司价值和看好公司未来发展的战略 投资者，共同推动医药产业的创新发展，国邦医药集团股份有限公司（以下简称 "公司"、"目标公司"、"国邦医药"）持股 5%以上股东潍坊仕琦汇股权投资合 伙企业（有限合伙）（以下简称"仕琦汇" 、"转让方 1"）、潍坊洪德辉股权投资 合伙企业（有限合伙）（以下简称"洪德辉"、"转让方 2"）及绍兴世庆德企业管理 咨询合伙企业（有限合伙）（以下简称"世庆德"、"转让方 3"）于 2025 年 8 月 20 日与浙江省国有资本运营有限公司（以下简称"国有运营公司"、"受让方"）签署 了《股份转让协议》（以下简称"本协议"），仕琦汇、洪德辉及世庆德拟通过协 议转让的方式向国有运营公司转让其首次公开发行股票前持有的公司股份 38,306,303 ...

Core Viewpoint - Guobang Pharmaceutical (605507.SH) has signed a share transfer agreement with Zhejiang State-owned Capital Operation Co., Ltd. to transfer 38,306,303 shares, representing 6.85% of the total share capital, to support the company's strategic development in the pharmaceutical industry [1][2] Group 1 - The share transfer involves major shareholders, including Weifang Shiqihui Equity Investment Partnership, Weifang Hongdehui Equity Investment Partnership, and Shaoxing Shiqingde Enterprise Management Consulting Partnership, who will collectively hold 4.91% of the company's shares after the transfer [1] - The state-owned operation company aims to support the comprehensive development of the company in the pharmaceutical sector, focusing on areas such as industrial chain collaboration, new business cultivation, and capital operations [2] - Future cooperation will involve personnel exchanges and collaborative efforts in investment project evaluation, new technology validation, application scenarios, and think tank consulting, with specific details to be negotiated and formalized in subsequent agreements [2]